Nivolumab
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer
Trial Timeline
Jul 14, 2016 → Nov 7, 2024
NCT ID
NCT02743494About Nivolumab
Nivolumab is a phase 3 stage product being developed by Ono Pharmaceutical for Advanced Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02743494. Target conditions include Advanced Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03987815 | Phase 2 | UNKNOWN |
| NCT03383458 | Phase 3 | Active |
| NCT03090737 | Phase 2 | Completed |
| NCT02857426 | Phase 2 | Completed |
| NCT02743494 | Phase 3 | Completed |
| NCT02632409 | Phase 3 | Active |
| NCT02387996 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Cancer